Target intervention against multiple‐risk markers to reduce cardiovascular disease in patients with type 2 diabetes

References

• Wingard DL, Barrett-Connor EL. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MS, Boyko EJ, Rieber GE, Bennet PH, editors. Diabetes in America. 2nd edn. Washing-ton: National Institutes of Health; 1995:429–48.
   Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart-disease in subjects with type-2 diabetes and in nondiabetic subjects with and without prior myocardial-infarction. N Engl J Med 1998;339: 229–34.
   Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japa-nese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–17.
   PubMed Web of Science ®Google Scholar
• UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treat-ment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–53.
   PubMed Web of Science ®Google Scholar
• UKPDS Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–65.
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755–62.
   PubMed Web of Science ®Google Scholar
• Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hyper-tension in the Elderly Program Cooperative Research Group. JAMA 1996;276:1886–92.
   Google Scholar
• Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997350:757–64.
   Google Scholar
• UKPDS Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–13.
   Google Scholar
• Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovas-cular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611–6.
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a random-ised trial against atenolol. Lancet 2002;359:1004–10.
   Google Scholar
• Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645–52.
   PubMed Web of Science ®Google Scholar
• Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Dia-betes Care 1998;21:597–603.
   Google Scholar
• Brown MJ, Palmer CR, Castaigne, de Leeuw PW, Mancia G, Rosenthal TA, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hyperten-sion Treatment (INSIGHT). Lancet 2000;356:366–72.
   Google Scholar
• Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359–65.
   Google Scholar
• Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new anti-hypertensive drugs in elderly patients: cardiovascular mortal-ity and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751–6.
   PubMed Web of Science ®Google Scholar
• Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620–5.
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hyper-tension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999;340:677–84.
   Google Scholar
• Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafi-brate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Dia-betes Care 1998;21: 641–8.
   Google Scholar
• Diabetes Atherosclerosis Intervention Study (DAIS). Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357: 905–10.
   Google Scholar
• Pyörälä K, Pedersen TR, Kjekshus J, Faergeman 0, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20: 614–20.
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average choles-terol levels. Cholesterol and Recurrent Events Trial investi-gators. N Engl J Med 1996;335:1001–9.
   Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57.
   Google Scholar
• Heart Protection Study (HPS). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360: 7–22.
   Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 2005–16.
   Google Scholar
• Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients. BMJ 1994; 308:81–106.
   Google Scholar
• de Gaetano G. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357:89–95.
   Google Scholar
• Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321: 129–35.
   Google Scholar
• ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992;268:1292–300.
   Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, rami-pril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–53.
   PubMed Web of Science ®Google Scholar
• The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996;39:587–93.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephro-pathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456–62.
   PubMed Web of Science ®Google Scholar
• Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhi-bition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996;156: 286–9.
   Google Scholar
• Parving HE, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Amer P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: 870–8.
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60.
   PubMed Web of Science ®Google Scholar
• The Multiple Risk Factor Intervention Trial (MRFIT). Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982;248:1465–77.
   Google Scholar
• UKPDS Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, Metabolism 1990;39: 905–12.
   Google Scholar
• de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454–9.
   PubMed Web of Science ®Google Scholar
• Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study. Am J Clin Nutr 2003;77:319–25.
   PubMed Web of Science ®Google Scholar
• Eriksson J, Taimela S, Koivisto VA. Exercise and the metabolic syndrome. Diabetologia 1997;40:125–35.
   Google Scholar
• Gxde P, Vedel P, Larsen N, Jensen GV, Parving HH, Pederse O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–93.
   Google Scholar
• Glasgow RE, McCaul KD, Schafer LC. Barriers to regimen adherence among persons with insulin-dependent diabetes. J Behav Med 1986;9:65–77.
   Google Scholar
• Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990;336: 542–5.
   PubMed Web of Science ®Google Scholar
• Logan AG, Milne BJ, Achber C, Campbell WP, Haynes RB. Work-site treatment of hypertension by specially trained nurses. A controlled trial. Lancet 1979;2:1175–8.
   Google Scholar
• Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of daily dosing frequency on patient medi-cation compliance. Arch Intern Med 1990;150:1881–4.
   Google Scholar
• Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 8O'/. BMJ 2003;326:1419.
   PubMed Web of Science ®Google Scholar
• Olivarius NF, Beck-Nielsen H, Andreasen AH, Horder M, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ 2001323:970–5.
   Google Scholar